METHYLPHENIDATE EXTENDED RELEASE for Attention deficit/hyperactivity disorder: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 17 adverse event reports in the FDA FAERS database where METHYLPHENIDATE EXTENDED RELEASE was used for Attention deficit/hyperactivity disorder.
Most Reported Side Effects for METHYLPHENIDATE EXTENDED RELEASE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Drug effect decreased | 17 | 53.1% | 0 | 0 |
| Drug ineffective | 11 | 34.4% | 0 | 0 |
| Drug effect increased | 8 | 25.0% | 0 | 0 |
| Feeling abnormal | 6 | 18.8% | 0 | 0 |
Other Indications for METHYLPHENIDATE EXTENDED RELEASE
Other Drugs Used for Attention deficit/hyperactivity disorder
METHYLPHENIDATE (9,093)
RISPERIDONE (6,071)
LISDEXAMFETAMINE DIMESYLATE (3,793)
ATOMOXETINE (3,703)
AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (3,164)
DAYTRANA (1,139)
GUANFACINE (896)
AMPHETAMINE\DEXTROAMPHETAMINE (407)
DEXMETHYLPHENIDATE (378)
ARIPIPRAZOLE (372)